NDAORALTABLET
Approved
Mar 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
10
Data completeness
3/8 — Basic
VIOXX (rofecoxib) by Merck & Co.. Approved for postoperative pain, osteoarthritis, rheumatoid arthritis and 1 more indications. First approved in 2004.
Drug data last refreshed 1w ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIOXX (rofecoxib) is an oral COX-2 selective inhibitor indicated for osteoarthritis, rheumatoid arthritis, acute pain, and postoperative pain. It was approved in March 2004 as a tablet formulation by Merck & Co. The drug works by selectively inhibiting cyclooxygenase-2 (COX-2), reducing inflammation and pain while aiming to spare gastrointestinal toxicity associated with non-selective NSAIDs.
LOE Approaching
VIOXX is approaching loss of exclusivity with diminishing market protection; commercial teams face portfolio transition planning and reduced headcount expectations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (4)
Worked on VIOXX at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.